Research and Markets: Men's Health Therapeutics Market to 2016 - in-Depth Analysis of the Unmet Needs, Drivers & Barriers Affecting the Men's Health Market

Research and Markets (http://www.researchandmarkets.com/research/e3fec8/mens_health_thera) has announced the addition of the "Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market" report to their offering.

Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors will Dominate the Market. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global men's health market. The report analyzes the markets for mens health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Global Men's Health Market is Forecast to Show Moderate Growth during the Forecast Period

In 2009, the global men's health market was estimated to be worth $4,019m, representing a cumulative annual growth rate (CAGR) of 7.9% between 2001 and 2009. By 2016, the global mens health market is estimated to reach $5,509m, indicating a CAGR of 4.6% between 2009 and 2016. The major reason for the reduced growth rate is the patent expiry of a blockbuster drug.

This blockbuster drug is Viagra. The drug contributes significantly to the entire mens health market. Hence, patent expiry of the drug will directly affect market growth.

The men's health pipeline portfolio comprises me-too and first-in-class molecules in the late stage of development. These molecules are expected to be launched during the forecast period. Some of these pipeline candidates offer improved therapeutic outcomes and a better safety profile compared to current market products. If launched, these drugs will offer physicians and patients better treatment options. This will boost the market growth.

In addition, a steady increase in the prevalence population and in the prescription population will sustain the modest market growth during the forecast period.

Scope:

• Annualized market data for the mens health market from 2001 to 2009, forecast forward to 2016.
• Analysis of the leading therapeutic segments, including erectile dysfunction, male hypogonadism and premature ejaculation.
• Analysis of the mens health market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.
• Market characterization of the mens health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.
• Key drivers and barriers that have a significant impact on the market.
• Coverage of pipeline molecules in various phases of drug development.
• Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Inc., Abbott Laboratories, Endo-Pharmaceuticals Holding Inc., Janssen-Cilag EMEA, VIVUS Inc., Auxilium Pharmaceuticals, Inc., APP Pharmaceuticals, Inc, Columbia Laboratories, Inc., Watson Pharmaceuticals, Inc. and Valeant Pharmaceuticals International.
• Key M&A activities, licensing agreements, that have taken place in 2009 in the global mens health market.

Reasons to buy:

The report will enhance your decision making capability. It will allow you to

• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
• Develop key strategic initiatives by understanding the key focus areas of leading companies.
• Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Key Topics Covered:

1 List of Tables and Figures

2 Global Men's Health Therapeutics Market: Scope of Research

3 Global Men's Health Therapeutics Market: Market Characterization

4 Global Erectile Dysfunction Therapeutics Market

5 Global Male Hypogonadism Therapeutics Market

6 Global Premature Ejaculation (PE) Therapeutics Market

7 Global Men's Health Market: Geographical Landscape

8 Global Men's Health Market: Pipeline Analysis

9 Global Men's Health Market: Competitive Landscape

10 Global Men's Health Market: Strategic Consolidations

11 Global Men's Health Therapeutics Market : Appendix

Companies Mentioned:

• Pfizer Inc.
• Eli Lilly and Company
• GlaxoSmithKline, Inc
• Abbott Laboratories (Abbott acquired Solvay Pharmaceuticals)
• Endo Pharmaceuticals Holding Inc.
• Janssen-Cilag EMEA
• VIVUS, Inc.
• Auxilium Pharmaceuticals, Inc.
• APP Pharmaceuticals (acquired by Fresenius Kabi Pharmaceuticals)
• Columbia Laboratories, Inc.
• Watson Pharmaceutical, Inc.
• Valeant Pharmaceuticals International

For more information visit http://www.researchandmarkets.com/research/e3fec8/mens_health_thera